Synergy Pharmaceuticals Inc (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and …
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) announced last week plans to delay the release timeline of Phase 3 trial data that evaluates the treating success …
Analyst Tim Chiang of BTIG expresses his concern about the slowdown in Synergy Pharmaceuticals Inc’s (NASDAQ:SGYP) Phase 3 trials for plecanatide, a treatment for …
In a research report released Friday, Canaccord analyst John Newman reiterated a Buy rating on shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) with a $13.00 …
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) announced it has reached the Food and Drug Administration (FDA) mid-cycle review milestone for the plecanatide new drug application …
Rodman & Renshaw analyst Ram Selvaraju weighed in today with a few insights on Synergy Pharmaceuticals Inc (NASDAQ:SGYP), ahead of the the upcoming Phase 3 …
Digestive Disease Week, an annual gathering of physicians and researchers in the fields of gastrointestinal surgery, hepatology, endoscopy, and gastroenterology, took place last …
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) released positive data this week and Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) had an investor event, leading analysts to share updated …
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) presented new in vitro data at Digestive Disease Week (DDW) showing plecanatide, an investigational compound being evaluated for chronic …
Analysts weigh in on drug makers Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Synergy Pharmaceuticals Inc (NASDAQ:SGYP), and EXACT Sciences Corporation (NASDAQ:EXAS). While Valeant just hosted an investor …
